Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.86 USD | -7.43% | -6.00% | -7.25% |
04-30 | Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Lyra Therapeutics, Inc. Announces Board Changes | CI |
Business Summary
Number of employees: 88
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Integrated Drug and Drug Delivery Solutions
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +14.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +14.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 31/12/14 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 12/09/21 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 10/07/22 |
Vineeta Belanger
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/19 |
John Bishop
CTO | Chief Tech/Sci/R&D Officer | 62 | 26/02/23 |
Ellen Cavaleri
IRC | Investor Relations Contact | - | 31/12/21 |
Ronan O’Brien
LAW | General Counsel | 52 | 15/10/23 |
Corinne Noyes
PRN | Corporate Officer/Principal | 56 | 31/08/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 15/02/22 |
W. Smith
BRD | Director/Board Member | 68 | 18/11/19 |
James Tobin
BRD | Director/Board Member | 79 | 06/03/22 |
C. Merrifield
BRD | Director/Board Member | 73 | 03/09/19 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 27/10/20 |
Michael Altman
BRD | Director/Board Member | 42 | 31/05/18 |
Maria Palasis
CEO | Chief Executive Officer | 59 | 31/12/14 |
Director/Board Member | 40 | 28/01/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,743,123 | 46,281,091 ( 77.47 %) | 0 | 77.47 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.25% | 320M | |
+25.81% | 42.68B | |
-2.70% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.97% | 24.94B | |
-20.59% | 18.96B | |
+29.41% | 12.3B | |
-2.66% | 11.95B | |
-1.13% | 11.55B |
- Stock Market
- Equities
- LYRA Stock
- Company Lyra Therapeutics, Inc.